secwatch.observer — SEC 8-K summary
======================================

Issuer:     Taysha Gene Therapies, Inc. (TSHA)
CIK:        0001806310
Form:       8-K
Filed at:   2022-11-08T23:59:59+00:00
Accession:  0001193125-22-279648
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Taysha Q3 net loss narrows to $26.3M; Astellas $50M investment extends cash runway
--------------------------------------------------------------------------------

- Net loss $26.3M ($0.64/sh) vs $51.2M ($1.35/sh) Q3 2021; R&D expenses down to $16.4M.
- Astellas invests $50M for 15% stake, options to license TSHA-120 (GAN) and TSHA-102 (Rett).
- Cash $34.3M at Sept 30; plus Astellas $50M and $25.6M net from Oct offering, runway into Q1 2024.
- Type B end-of-Phase 2 FDA meeting for TSHA-120 on Dec 13, 2022; regulatory update in Jan 2023.
- Preliminary TSHA-102 adult data and pediatric trial start expected in H1 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1806310/000119312522279648/0001193125-22-279648-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1806310/000119312522279648/d411971d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-22-279648

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer